(Q34129981)

31 July 2017

1 reference

title

Recent advances of IMiDs in cancer therapy (English)

1 reference

31 July 2017

Shirong Li

1

1 reference

31 July 2017

Navkiranjit Gill

2

1 reference

31 July 2017

Suzanne Lentzsch

3

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20689431

17 June 2024

publication date

1 November 2010

1 reference

full work available at URL

31 July 2017

https://journals.lww.com/10.1097/CCO.0b013e32833d752c

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Current Opinion in Oncology

17 June 2024

published in

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

579-585

1 reference

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

31 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Mechanism of action of lenalidomide in hematological malignancies

17 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

17 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Thalidomide inhibits activation of caspase-1.

17 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

17 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

17 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

17 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

17 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

17 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

17 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis

17 June 2024

11

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

17 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

17 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

17 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide: a novel anticancer drug with multiple modalities

17 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

17 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

17 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

17 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.

17 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

17 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

17 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

17 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma

17 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1.

17 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients

17 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

17 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

17 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

17 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

17 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

17 June 2024

30

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

17 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

17 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

17 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/CCO.0B013E32833D752C

17 June 2024

Identifiers

1 reference

31 July 2017

1 reference